世界のデュシェンヌ型筋ジストロフィー(DMD)治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5718
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、97ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、デュシェンヌ型筋ジストロフィー(DMD)治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（エテプリルセン、デフラザコート、アタルレン）、用途別市場規模（病院、診療所、ホームケア）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・デュシェンヌ型筋ジストロフィー(DMD)治療薬の市場動向
・企業の競争状況、市場シェア
・デュシェンヌ型筋ジストロフィー(DMD)治療薬の種類別市場規模と予測2016-2027（エテプリルセン、デフラザコート、アタルレン）
・デュシェンヌ型筋ジストロフィー(DMD)治療薬の用途別市場規模と予測2016-2027（病院、診療所、ホームケア）
・デュシェンヌ型筋ジストロフィー(DMD)治療薬の北米市場規模2016-2027（アメリカ、カナダ）
・デュシェンヌ型筋ジストロフィー(DMD)治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・デュシェンヌ型筋ジストロフィー(DMD)治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・デュシェンヌ型筋ジストロフィー(DMD)治療薬の中南米市場規模2016-2027（メキシコ、ブラジル）
・デュシェンヌ型筋ジストロフィー(DMD)治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Sarepta Therapeutics、PTC Therapeutics、Pfizer、Bristol-Myers Squibb、Italfarmaco、Santhera Pharmaceuticals、WaVe life Science）
・結論

Market Analysis and Insights: Global Drugs for Duchenne Muscular Dystrophy (DMD) Market
The global Drugs for Duchenne Muscular Dystrophy (DMD) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Drugs for Duchenne Muscular Dystrophy (DMD) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Drugs for Duchenne Muscular Dystrophy (DMD) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Drugs for Duchenne Muscular Dystrophy (DMD) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Drugs for Duchenne Muscular Dystrophy (DMD) market.

Global Drugs for Duchenne Muscular Dystrophy (DMD) Scope and Market Size
Drugs for Duchenne Muscular Dystrophy (DMD) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Drugs for Duchenne Muscular Dystrophy (DMD) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Eteplirsen
Deflazacort
Ataluren

Segment by Application
Hospitals
Clinics
Home Care

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
WaVe life Science

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Eteplirsen
1.2.3 Deflazacort
1.2.4 Ataluren
1.3 Market by Application
1.3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Perspective (2016-2027)
2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Growth Trends by Regions
2.2.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Historic Market Share by Regions (2016-2021)
2.2.3 Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Regions (2022-2027)
2.3 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Dynamic
2.3.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Trends
2.3.2 Drugs for Duchenne Muscular Dystrophy (DMD) Market Drivers
2.3.3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Challenges
2.3.4 Drugs for Duchenne Muscular Dystrophy (DMD) Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Players by Revenue
3.1.1 Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Players by Revenue (2016-2021)
3.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Players (2016-2021)
3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue
3.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Concentration Ratio
3.4.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in 2020
3.5 Drugs for Duchenne Muscular Dystrophy (DMD) Key Players Head office and Area Served
3.6 Key Players Drugs for Duchenne Muscular Dystrophy (DMD) Product Solution and Service
3.7 Date of Enter into Drugs for Duchenne Muscular Dystrophy (DMD) Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Drugs for Duchenne Muscular Dystrophy (DMD) Breakdown Data by Type
4.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Historic Market Size by Type (2016-2021)
4.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Type (2022-2027)

5 Drugs for Duchenne Muscular Dystrophy (DMD) Breakdown Data by Application
5.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Historic Market Size by Application (2016-2021)
5.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2016-2027)
6.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
6.2.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021)
6.2.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027)
6.2.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2027)
6.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
6.3.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021)
6.3.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027)
6.3.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2027)
6.4 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
6.4.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021)
6.4.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2016-2027)
7.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
7.2.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021)
7.2.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027)
7.2.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2027)
7.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
7.3.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021)
7.3.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027)
7.3.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2027)
7.4 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
7.4.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021)
7.4.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2016-2027)
8.2 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
8.2.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2027)
8.3 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
8.3.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2027)
8.4 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
8.4.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2016-2027)
9.2 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
9.2.1 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021)
9.2.2 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027)
9.2.3 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2027)
9.3 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
9.3.1 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021)
9.3.2 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027)
9.3.3 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2027)
9.4 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
9.4.1 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021)
9.4.2 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2016-2027)
10.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
10.2.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2027)
10.3 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
10.3.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2027)
10.4 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
10.4.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
11.1.4 Sarepta Therapeutics Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
11.1.5 Sarepta Therapeutics Recent Development
11.2 PTC Therapeutics
11.2.1 PTC Therapeutics Company Details
11.2.2 PTC Therapeutics Business Overview
11.2.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
11.2.4 PTC Therapeutics Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
11.2.5 PTC Therapeutics Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
11.3.4 Pfizer Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
11.4.4 Bristol-Myers Squibb Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Italfarmaco
11.5.1 Italfarmaco Company Details
11.5.2 Italfarmaco Business Overview
11.5.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
11.5.4 Italfarmaco Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
11.5.5 Italfarmaco Recent Development
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Details
11.6.2 Santhera Pharmaceuticals Business Overview
11.6.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
11.6.4 Santhera Pharmaceuticals Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
11.6.5 Santhera Pharmaceuticals Recent Development
11.7 WaVe life Science
11.7.1 WaVe life Science Company Details
11.7.2 WaVe life Science Business Overview
11.7.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
11.7.4 WaVe life Science Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
11.7.5 WaVe life Science Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Eteplirsen
Table 3. Key Players of Deflazacort
Table 4. Key Players of Ataluren
Table 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Regions (2016-2021)
Table 9. Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Regions (2022-2027)
Table 11. Drugs for Duchenne Muscular Dystrophy (DMD) Market Trends
Table 12. Drugs for Duchenne Muscular Dystrophy (DMD) Market Drivers
Table 13. Drugs for Duchenne Muscular Dystrophy (DMD) Market Challenges
Table 14. Drugs for Duchenne Muscular Dystrophy (DMD) Market Restraints
Table 15. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Players (2016-2021)
Table 17. Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) as of 2020)
Table 18. Ranking of Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Drugs for Duchenne Muscular Dystrophy (DMD) Product Solution and Service
Table 22. Date of Enter into Drugs for Duchenne Muscular Dystrophy (DMD) Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2016-2021)
Table 26. Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2016-2021)
Table 30. Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027) & (US$ Million)
Table 62. Sarepta Therapeutics Company Details
Table 63. Sarepta Therapeutics Business Overview
Table 64. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product
Table 65. Sarepta Therapeutics Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021) & (US$ Million)
Table 66. Sarepta Therapeutics Recent Development
Table 67. PTC Therapeutics Company Details
Table 68. PTC Therapeutics Business Overview
Table 69. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product
Table 70. PTC Therapeutics Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021) & (US$ Million)
Table 71. PTC Therapeutics Recent Development
Table 72. Pfizer Company Details
Table 73. Pfizer Business Overview
Table 74. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product
Table 75. Pfizer Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021) & (US$ Million)
Table 76. Pfizer Recent Development
Table 77. Bristol-Myers Squibb Company Details
Table 78. Bristol-Myers Squibb Business Overview
Table 79. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product
Table 80. Bristol-Myers Squibb Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021) & (US$ Million)
Table 81. Bristol-Myers Squibb Recent Development
Table 82. Italfarmaco Company Details
Table 83. Italfarmaco Business Overview
Table 84. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product
Table 85. Italfarmaco Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021) & (US$ Million)
Table 86. Italfarmaco Recent Development
Table 87. Santhera Pharmaceuticals Company Details
Table 88. Santhera Pharmaceuticals Business Overview
Table 89. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product
Table 90. Santhera Pharmaceuticals Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021) & (US$ Million)
Table 91. Santhera Pharmaceuticals Recent Development
Table 92. WaVe life Science Company Details
Table 93. WaVe life Science Business Overview
Table 94. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product
Table 95. WaVe life Science Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021) & (US$ Million)
Table 96. WaVe life Science Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type: 2020 VS 2027
Figure 2. Eteplirsen Features
Figure 3. Deflazacort Features
Figure 4. Ataluren Features
Figure 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Home Care Case Studies
Figure 9. Drugs for Duchenne Muscular Dystrophy (DMD) Report Years Considered
Figure 10. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Regions: 2020 VS 2027
Figure 13. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Regions (2022-2027)
Figure 14. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Players in 2020
Figure 15. Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in 2020
Figure 17. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2016-2021)
Figure 18. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2022-2027)
Figure 19. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2016-2027)
Figure 21. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2016-2027)
Figure 22. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2016-2027)
Figure 23. United States Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2016-2027)
Figure 27. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2016-2027)
Figure 28. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2016-2027)
Figure 29. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region (2016-2027)
Figure 39. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2016-2027)
Figure 47. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2016-2027)
Figure 48. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2016-2027)
Figure 49. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2016-2027)
Figure 55. Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Sarepta Therapeutics Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
Figure 59. PTC Therapeutics Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
Figure 60. Pfizer Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
Figure 62. Italfarmaco Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
Figure 63. Santhera Pharmaceuticals Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
Figure 64. WaVe life Science Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

以下、関連資料のご紹介

デュシェンヌ型筋ジストロフィーのグローバル市場2021

Global Duchenne Muscular Dystrophy Sales Market Report 2021
QAF27660 2021年4月20日 136Pages
本市場調査資料では、世界のデュシェンヌ型筋ジストロフィー市場について種類別（デフラザコート、プレドニゾン、その他）、用途別（男性用、女性用）、地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2016年～2027年までの市場規模と予測（販売量、売上、価格）、...

世界の脊髄性筋萎縮症（SMA）治療薬市場規模・現状・予測（2021年-2027年）

Global Spinal Muscular Atrophy (SMA) Drugs Market Size, Status and Forecast 2021-2027
QFJ1-4894 2021年6月 87Pages
QYResearch社発行の本調査レポートでは、脊髄性筋萎縮症（SMA）治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口薬、注射薬）、用途別市場規模（乳児、子供、大人）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、...

世界のゴーシェ病（GD）治療薬市場規模・現状・予測（2021年-2027年）

Global Gaucher Disease (GD) Drugs Market Size, Status and Forecast 2021-2027
QFJ1-5747 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、ゴーシェ病（GD）治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（酵素補充療法、基質減少療法）、用途別市場規模（非神経障害性ゴーシェ病、神経障害性ゴーシェ病）、主要地域別市場規模（北米、アメリカ...

世界の遅発性ジスキネジア(TD)治療薬市場規模・現状・予測（2021年-2027年）

Global Tardive Dyskinesia (TD) Treatment Drugs Market Size, Status and Forecast 2021-2027
QFJ1-6032 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、遅発性ジスキネジア(TD)治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（バルベナジン、デュテトラベナジン）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、ア...

世界の腎臓癌＆腎細胞癌（RCC）治療薬市場規模・現状・予測（2021年-2027年）

Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, Status and Forecast 2021-2027
QFJ1-5819 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、腎臓癌＆腎細胞癌（RCC）治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アフィニトール（エベロリムス）、アバスチン（ベバシズマブ）、カボメティ（カボザンチニブ）、インリタ（アキシチニブ）、ネク...

世界の網膜ジストロフィー治療市場規模・現状・予測（2021年-2027年）

Global Retinal Dystrophy Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4827 2021年6月 105Pages
QYResearch社発行の本調査レポートでは、網膜ジストロフィー治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（遺伝子治療、対症療法）、用途別市場規模（病院、専門クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中...

世界の脊髄性筋萎縮症（SMA）治療市場規模・現状・予測（2021年-2027年）

Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size, Status and Forecast 2021-2027
QFJ1-5351 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、脊髄性筋萎縮症（SMA）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ヌシネルセン、オナセムノゲンアベパルボベック）、用途別市場規模（タイプ1SMA、タイプ2 SMA、その他）、主要地域別市場規...

世界の脊髄性筋萎縮症遺伝子検出市場規模・現状・予測（2021年-2027年）

Global Spinal Muscular Atrophy Genetic Detection Market Size, Status and Forecast 2021-2027
QFJ1-4895 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、脊髄性筋萎縮症遺伝子検出の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（遺伝子スクリーニング、生殖遺伝子検査、診断検査、遺伝子保因者検査、発症前検査）、用途別市場規模（病院、クリニック、診断センター）...

世界の球脊髄性筋萎縮症治療市場規模・現状・予測（2021年-2027年）

Global Spinal and Bulbar Muscular Atrophy Treatment Market Size, Status and Forecast 2021-2027
QFJ1-6018 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、球脊髄性筋萎縮症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（5α-レダクターゼ阻害剤、ゴナドトロピン放出ホルモンアゴニスト）、用途別市場規模（病院、整形外科クリニック、外来手術センター）、主要...

世界のmRNAワクチン＆治療薬市場規模・現状・予測（2021年-2027年）

Global mRNA Vaccine And Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-4530 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、mRNAワクチン＆治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（感染症、がん、その他）、用途別市場規模（病院、研究所）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、イン...

デュシェンヌ型筋ジストロフィーのグローバル市場2021 uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle w…
世界の脊髄性筋萎縮症（SMA）治療薬市場規模・現状・予測（2021年-2027年） Spinal Muscular Atrophy (SMA), also known as spinal muscular atrophy, is a type of disease in which the degeneration of motor neurons in the anterior horn of the spinal cord leads to muscle weakness and muscular atrophy.The Spinal muscular atrophy drugs Can effectively alleviate the symptoms of the …
世界の網膜ジストロフィー治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Retinal Dystrophy Treatment Market The global Retinal Dystrophy Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity…
世界の脊髄性筋萎縮症（SMA）治療市場規模・現状・予測（2021年-2027年） Spinal muscular atrophy treatment market growth is driven by a significant increase in the number of product launches despite the relative rarity of the disorder and high costs associated with the approved drugs. The treatment of spinal muscular atrophy through the gene therapy drug called Zolgensma…
世界のがん支持療法薬剤市場規模・現状・予測（2021年-2027年） Supportive drugs are not anticancer drugs. They protect certain cells or organs from the side effects of chemotherapy drugs or radiation therapy. Increasing uptake of biosimilars, rising expenditure on healthcare, and availability of effective treatment methods, including target specific and tailore…